| Name | Title | Contact Details |
|---|
MCR American Pharmaceuticals, Inc. was established in 1991. Our product line consists of Allfen, Ambifed, Ambi, Maxifed, Maxinate, Maxiphen, Promacet and Time-Hist QD. Our sales representatives are located throughout the United States. We will continue
Falks Woodland Pharmacy, Inc. is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Regenerative Processing Plant is a biotechnology company that manufactures various stem cell stimulants using patented D MAPPS technology. They offer a wide range of innovative high quality soft tissue and wound care products for tissue regeneration.
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
Aridis is a privately held biotechnology company located in San Jose, CA, USA which is focused on infectious diseases. Aridis has a strong portfolio of anti-infective product candidates, a human monoclonal antibody discovery platform technology, and best-in-class formulation technologies available for partnering. Our product portfolio comprises two monoclonal antibodies currently at Phase 2 clinical testing in patients, and two additional anti-infective drug candidates entering the IND development stage. Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly impact current approaches to infection control. Aridis has raised over $20m in grant funding from leading institutions such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health and Human Services’ BARDA, USAID, PATH/Gates Foundations, and Regional Centers of Excellence.